다형성 교모세포종(GBM) 치료 시장 분석 및 예측(-2035년) : 유형별, 제품 유형별, 기술별, 용도별, 최종 사용자별, 기기별, 단계별, 서비스별, 도입 형태별, 기능별

Glioblastoma Multiforme (GBM) Treatment Market is anticipated to expand from $3.6 billion in 2024 to $8.1 billion by 2034, growing at a CAGR of approximately 10%. The Glioblastoma Multiforme (GBM) Treatment Market encompasses therapies targeting aggressive brain tumors, including surgery, radiation, chemotherapy, and emerging immunotherapies. It aims to extend patient survival and improve quality of life. Advances in molecular diagnostics and personalized medicine are driving innovation, while the high unmet need and prevalence spur market growth. Strategic collaborations and research investments are pivotal in developing novel treatments and enhancing therapeutic efficacy.

The Glioblastoma Multiforme (GBM) Treatment Market is evolving, driven by advancements in therapeutic approaches and increasing research investments. The chemotherapy segment leads in performance, with temozolomide being the most widely used due to its efficacy in extending patient survival. Immunotherapy is the second highest performing segment, gaining momentum with promising results from checkpoint inhibitors and vaccine-based therapies. These innovations are reshaping treatment paradigms, offering hope for improved patient outcomes. Radiation therapy remains a critical component of GBM treatment, with stereotactic radiosurgery and intensity-modulated radiation therapy enhancing precision and minimizing damage to healthy tissue. The surgical segment is also witnessing advancements, with minimally invasive techniques and neuro-navigation systems improving resection accuracy. Emerging treatment modalities, such as gene therapy and targeted drug delivery systems, are attracting significant interest, reflecting a shift towards personalized medicine. Collaborations between pharmaceutical companies and research institutions are accelerating the development of novel therapeutics, presenting lucrative opportunities for market growth.

The Glioblastoma Multiforme (GBM) Treatment Market is characterized by a dynamic landscape with diverse market share distribution among key players. Pricing strategies are increasingly competitive, reflecting both innovation and the introduction of new treatment modalities. Recent product launches have focused on targeted therapies and personalized medicine, aiming to improve patient outcomes. The market is witnessing a shift towards novel therapeutic approaches, including immunotherapy and gene editing, which are reshaping treatment paradigms and offering promising avenues for growth. Competition benchmarking reveals a robust presence of established pharmaceutical giants alongside emerging biotech firms. Regulatory influences, particularly in North America and Europe, are pivotal in shaping market dynamics, with stringent approval processes impacting the speed of new product introductions. The competitive landscape is marked by strategic collaborations and mergers, enhancing research capabilities and market reach. Regulatory frameworks continue to evolve, with an emphasis on patient safety and efficacy, driving innovation while presenting challenges in compliance and market entry.

Geographical Overview:

The Glioblastoma Multiforme (GBM) treatment market is witnessing varied growth patterns across different regions. North America remains at the forefront, driven by advanced healthcare infrastructure and significant research investments. The presence of leading pharmaceutical companies and active clinical trials contributes to its dominance. Europe follows, benefiting from strong regulatory support and increasing healthcare expenditure. The region's focus on innovative therapies and personalized medicine further propels market growth. Asia Pacific is emerging as a lucrative market, with rising healthcare awareness and improving medical facilities. Countries like China and India are investing heavily in healthcare, fostering growth in GBM treatment. Latin America and the Middle East & Africa are nascent markets with promising potential. Brazil and South Africa are key countries showing increased interest in modern oncology treatments. Enhanced healthcare policies and growing patient awareness in these regions are expected to drive demand for advanced GBM therapies, creating new growth pockets in the global market.

The Glioblastoma Multiforme (GBM) Treatment Market is significantly influenced by global tariffs, geopolitical tensions, and evolving supply chain dynamics. In Japan and South Korea, reliance on imported pharmaceuticals prompts strategic shifts towards local R&D investments to mitigate tariff impacts. China's focus on self-sufficiency in drug production is accelerated by trade restrictions, fostering innovation in GBM therapies. Taiwan's robust biotech sector remains vital, yet faces geopolitical risks from regional tensions. Globally, the GBM treatment market is experiencing steady growth, driven by advancements in personalized medicine and immunotherapy. By 2035, market evolution will hinge on collaborative research and diversified supply chains. Middle East conflicts could exacerbate supply chain disruptions, indirectly affecting production costs and timelines through volatile energy prices.

Key Trends and Drivers:

The Glioblastoma Multiforme (GBM) Treatment Market is experiencing dynamic growth, propelled by increasing incidence rates and advancements in therapeutic approaches. A key trend is the development of personalized medicine, which tailors treatment based on individual genetic profiles, enhancing efficacy and patient outcomes. Immunotherapy is gaining traction as a promising treatment option, leveraging the body's immune system to combat cancer cells more effectively. Another significant driver is the rise in research and development activities, leading to innovative drug formulations and delivery mechanisms. The growing collaboration between pharmaceutical companies and research institutions is accelerating the pace of new treatment discoveries. Additionally, regulatory support for orphan drugs provides incentives for developing GBM therapies, fostering further market expansion. Opportunities abound in emerging markets where healthcare infrastructure is improving, and access to advanced treatments is expanding. Companies focusing on affordable and accessible solutions are well-positioned to capture these growing markets. The integration of artificial intelligence in drug discovery and patient monitoring is also set to revolutionize the landscape, offering precision and efficiency in GBM treatment. As awareness and investment in cancer research grow, the GBM Treatment Market is poised for sustained advancement and innovation.

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Technology
• 2.4 Key Market Highlights by Application
• 2.5 Key Market Highlights by End User
• 2.6 Key Market Highlights by Device
• 2.7 Key Market Highlights by Stage
• 2.8 Key Market Highlights by Services
• 2.9 Key Market Highlights by Deployment
• 2.10 Key Market Highlights by Functionality

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Chemotherapy
  • 4.1.2 Radiotherapy
  • 4.1.3 Targeted Therapy
  • 4.1.4 Immunotherapy
  • 4.1.5 Tumor Treating Fields
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Drugs
  • 4.2.2 Devices
  • 4.2.3 Therapeutic Solutions
• 4.3 Market Size & Forecast by Technology (2020-2035)
  • 4.3.1 Gene Therapy
  • 4.3.2 Nanotechnology
  • 4.3.3 Biotechnology
• 4.4 Market Size & Forecast by Application (2020-2035)
  • 4.4.1 Primary Glioblastoma
  • 4.4.2 Secondary Glioblastoma
  • 4.4.3 Recurrent Glioblastoma
• 4.5 Market Size & Forecast by End User (2020-2035)
  • 4.5.1 Hospitals
  • 4.5.2 Specialty Clinics
  • 4.5.3 Ambulatory Surgical Centers
  • 4.5.4 Research Institutes
• 4.6 Market Size & Forecast by Device (2020-2035)
  • 4.6.1 MRI Scanners
  • 4.6.2 CT Scanners
  • 4.6.3 PET Scanners
• 4.7 Market Size & Forecast by Stage (2020-2035)
  • 4.7.1 Early Stage
  • 4.7.2 Advanced Stage
  • 4.7.3 Recurrent Stage
• 4.8 Market Size & Forecast by Services (2020-2035)
  • 4.8.1 Consultation Services
  • 4.8.2 Diagnostic Services
  • 4.8.3 Treatment Services
• 4.9 Market Size & Forecast by Deployment (2020-2035)
  • 4.9.1 On-premise
  • 4.9.2 Cloud-based
  • 4.9.3 Hybrid
• 4.10 Market Size & Forecast by Functionality (2020-2035)
  • 4.10.1 Diagnostic Functionality
  • 4.10.2 Therapeutic Functionality
  • 4.10.3 Monitoring Functionality

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Technology
    • 5.2.1.4 Application
    • 5.2.1.5 End User
    • 5.2.1.6 Device
    • 5.2.1.7 Stage
    • 5.2.1.8 Services
    • 5.2.1.9 Deployment
    • 5.2.1.10 Functionality
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Technology
    • 5.2.2.4 Application
    • 5.2.2.5 End User
    • 5.2.2.6 Device
    • 5.2.2.7 Stage
    • 5.2.2.8 Services
    • 5.2.2.9 Deployment
    • 5.2.2.10 Functionality
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Technology
    • 5.2.3.4 Application
    • 5.2.3.5 End User
    • 5.2.3.6 Device
    • 5.2.3.7 Stage
    • 5.2.3.8 Services
    • 5.2.3.9 Deployment
    • 5.2.3.10 Functionality
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Technology
    • 5.3.1.4 Application
    • 5.3.1.5 End User
    • 5.3.1.6 Device
    • 5.3.1.7 Stage
    • 5.3.1.8 Services
    • 5.3.1.9 Deployment
    • 5.3.1.10 Functionality
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Technology
    • 5.3.2.4 Application
    • 5.3.2.5 End User
    • 5.3.2.6 Device
    • 5.3.2.7 Stage
    • 5.3.2.8 Services
    • 5.3.2.9 Deployment
    • 5.3.2.10 Functionality
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Technology
    • 5.3.3.4 Application
    • 5.3.3.5 End User
    • 5.3.3.6 Device
    • 5.3.3.7 Stage
    • 5.3.3.8 Services
    • 5.3.3.9 Deployment
    • 5.3.3.10 Functionality
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Technology
    • 5.4.1.4 Application
    • 5.4.1.5 End User
    • 5.4.1.6 Device
    • 5.4.1.7 Stage
    • 5.4.1.8 Services
    • 5.4.1.9 Deployment
    • 5.4.1.10 Functionality
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Technology
    • 5.4.2.4 Application
    • 5.4.2.5 End User
    • 5.4.2.6 Device
    • 5.4.2.7 Stage
    • 5.4.2.8 Services
    • 5.4.2.9 Deployment
    • 5.4.2.10 Functionality
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Technology
    • 5.4.3.4 Application
    • 5.4.3.5 End User
    • 5.4.3.6 Device
    • 5.4.3.7 Stage
    • 5.4.3.8 Services
    • 5.4.3.9 Deployment
    • 5.4.3.10 Functionality
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Technology
    • 5.4.4.4 Application
    • 5.4.4.5 End User
    • 5.4.4.6 Device
    • 5.4.4.7 Stage
    • 5.4.4.8 Services
    • 5.4.4.9 Deployment
    • 5.4.4.10 Functionality
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Technology
    • 5.4.5.4 Application
    • 5.4.5.5 End User
    • 5.4.5.6 Device
    • 5.4.5.7 Stage
    • 5.4.5.8 Services
    • 5.4.5.9 Deployment
    • 5.4.5.10 Functionality
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Technology
    • 5.4.6.4 Application
    • 5.4.6.5 End User
    • 5.4.6.6 Device
    • 5.4.6.7 Stage
    • 5.4.6.8 Services
    • 5.4.6.9 Deployment
    • 5.4.6.10 Functionality
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Technology
    • 5.4.7.4 Application
    • 5.4.7.5 End User
    • 5.4.7.6 Device
    • 5.4.7.7 Stage
    • 5.4.7.8 Services
    • 5.4.7.9 Deployment
    • 5.4.7.10 Functionality
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Technology
    • 5.5.1.4 Application
    • 5.5.1.5 End User
    • 5.5.1.6 Device
    • 5.5.1.7 Stage
    • 5.5.1.8 Services
    • 5.5.1.9 Deployment
    • 5.5.1.10 Functionality
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Technology
    • 5.5.2.4 Application
    • 5.5.2.5 End User
    • 5.5.2.6 Device
    • 5.5.2.7 Stage
    • 5.5.2.8 Services
    • 5.5.2.9 Deployment
    • 5.5.2.10 Functionality
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Technology
    • 5.5.3.4 Application
    • 5.5.3.5 End User
    • 5.5.3.6 Device
    • 5.5.3.7 Stage
    • 5.5.3.8 Services
    • 5.5.3.9 Deployment
    • 5.5.3.10 Functionality
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Technology
    • 5.5.4.4 Application
    • 5.5.4.5 End User
    • 5.5.4.6 Device
    • 5.5.4.7 Stage
    • 5.5.4.8 Services
    • 5.5.4.9 Deployment
    • 5.5.4.10 Functionality
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Technology
    • 5.5.5.4 Application
    • 5.5.5.5 End User
    • 5.5.5.6 Device
    • 5.5.5.7 Stage
    • 5.5.5.8 Services
    • 5.5.5.9 Deployment
    • 5.5.5.10 Functionality
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Technology
    • 5.5.6.4 Application
    • 5.5.6.5 End User
    • 5.5.6.6 Device
    • 5.5.6.7 Stage
    • 5.5.6.8 Services
    • 5.5.6.9 Deployment
    • 5.5.6.10 Functionality
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Technology
    • 5.6.1.4 Application
    • 5.6.1.5 End User
    • 5.6.1.6 Device
    • 5.6.1.7 Stage
    • 5.6.1.8 Services
    • 5.6.1.9 Deployment
    • 5.6.1.10 Functionality
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Technology
    • 5.6.2.4 Application
    • 5.6.2.5 End User
    • 5.6.2.6 Device
    • 5.6.2.7 Stage
    • 5.6.2.8 Services
    • 5.6.2.9 Deployment
    • 5.6.2.10 Functionality
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Technology
    • 5.6.3.4 Application
    • 5.6.3.5 End User
    • 5.6.3.6 Device
    • 5.6.3.7 Stage
    • 5.6.3.8 Services
    • 5.6.3.9 Deployment
    • 5.6.3.10 Functionality
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Technology
    • 5.6.4.4 Application
    • 5.6.4.5 End User
    • 5.6.4.6 Device
    • 5.6.4.7 Stage
    • 5.6.4.8 Services
    • 5.6.4.9 Deployment
    • 5.6.4.10 Functionality
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Technology
    • 5.6.5.4 Application
    • 5.6.5.5 End User
    • 5.6.5.6 Device
    • 5.6.5.7 Stage
    • 5.6.5.8 Services
    • 5.6.5.9 Deployment
    • 5.6.5.10 Functionality

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Kazia Therapeutics
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Northwest Biotherapeutics
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Del Mar Pharmaceuticals
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Cortexyme
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Vascular Biogenics
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Agenus
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Merrimack Pharmaceuticals
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Diffusion Pharmaceuticals
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Ziopharm Oncology
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Oncoceutics
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 DNAtrix
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Immunomic Therapeutics
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Kintara Therapeutics
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Medicenna Therapeutics
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Candel Therapeutics
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Immuno Cellular Therapeutics
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Plus Therapeutics
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Tocagen
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Orbus Therapeutics
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Bexion Pharmaceuticals
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us